CAR T Cell Immunotherapy for Pancreatic Cancer

Summary

Phase I study to establish the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma

Timeline

Start

2017-09-15

Primary completion

2025-02-20

Completion

2025-02-20

Outcome

Outcome not reported

Stopped: “Administrative reasons”

Publications

• Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med. 2025 Sep 16;6(9):102301. doi: 10.1016/j.xcrm.2025.102301. Epub 2025 Aug 18.

Drugs

Indications